HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recur...

Full description

Bibliographic Details
Main Authors: Annika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, Anton W. Langerak, Alice F. Muggen, Rainer Claus, Irina Bonzheim, Falko Fend, Helmut Rainer Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanović, Alexander N. R. Weber
Format: Article
Language:English
Published: Taylor & Francis Group 2017-03-01
Series:OncoImmunology
Subjects:
cancer vaccine
hla ligandome
immunotherapy
myd88 l265p
neoantigen
non-hodgkin lymphoma
peptide vaccination
Online Access:http://dx.doi.org/10.1080/2162402X.2016.1219825

Internet

http://dx.doi.org/10.1080/2162402X.2016.1219825

Similar Items